Would let Medicaid and Medicare tie drug payments to patient results.
This bill would make it easier for government health programs like Medicaid and Medicare to pay for drugs based on how well they work for patients. It would set clear rules for these "value-based purchasing" deals. This changes how drug prices are reported and helps drug makers avoid legal problems. This could potentially improve patient access to certain drugs and affect costs.
Today, the rules for how Medicaid and Medicare can pay for drugs based on patient results are not clearly defined, which can make it hard for drug makers and states to use these deals. This bill would create clear rules for these "value-based purchasing arrangements," making it easier for them to be used and changing how drug prices are reported for these programs. It would also add a legal protection for certain payments made under these deals.
HR 7871 · 119th Congress · March 9, 2026 · AI Summary by gemini-2.5-flash · 9/10
Sign in to see your representatives' phone numbers